Research Papers:

Amalgamation of PI3K and EZH2 blockade synergistically regulates invasion and angiogenesis: combination therapy for glioblastoma multiforme

Vishnu S. Mishra, Naveen Kumar, Masoom Raza and Seema Sehrawat _

PDF  |  Full Text  |  Supplementary Files  |  How to cite

Oncotarget. 2020; 11:4754-4769. https://doi.org/10.18632/oncotarget.27842

Metrics: PDF 1156 views  |   Full Text 2768 views  |   ?  


Vishnu S. Mishra1,*, Naveen Kumar1,*, Masoom Raza1 and Seema Sehrawat1

1 Precision NeuroOncology & NeuroVascular Disease Modeling Group, Department of Life Sciences, School of Natural Sciences, Shiv Nadar University, NCR, 201314, India

* These authors contributed equally to this work

Correspondence to:

Seema Sehrawat,email: [email protected],
[email protected]

Keywords: precision neuroOncology; combination therapy; glioblastoma multiforme; pharmacological intervention; cytokine based proteomics

Received: May 18, 2020     Accepted: November 24, 2020     Published: December 22, 2020

Copyright: © 2020 Mishra et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Glioblastoma multiforme is known as the primary malignant and most devastating form of tumor in central nervous system of adult population. Amongst all CNS cancers, Glioblastoma multiforme GBM is a rare grade IV astrocytoma and it has the worst prognosis initiated by metastasis to supra-tentorial region of the brain. Current options for the treatment include surgery, radiation therapy and chemotherapy. Substantial information of its pathology and molecular signaling exposed new avenues for generating innovative therapies. In our study, we have undertaken a novel combination approach for GBM treatment. PI3K signaling participates in cancer progression and plays a significant role in metastasis. Here, we are targeting PI3K signaling pathways in glioblastoma along with EZH2, a known transcriptional regulator. We found that targeting transcriptional regulator EZH2 and PI3K affect cellular migration and morphological changes. These changes in signatory activities of cancerous cells led to inhibit its progression in vitro. With further analysis we confirmed the angiogenic inhibition and reduction in stem-ness potential of GBM. Later, cytokine proteome array analysis revealed several participants of metastasis and tumor induced angiogenesis using combination regime. This study provides a significant reduction in GBM progression investigated using Glioblastoma Multiforme U-87 cells with effective combination of pharmacological inhibitors PI-103 and EPZ-6438. This strategy will be further used to combat GBM more innovatively along with the existing therapies.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27842